FDA ACTIONS

FDA warns about dronedarone in AF patients

FDA recently warned that dronedarone (Multaq, Sanofi-Aventis) increases the risk of serious cardiovascular events–including death–when used by patients in permanent atrial fibrillation. » More

FDA revises simvastatin dose when combined with amiodarone

FDA revised the dose limitation for simvastatin from 10 mg to 20 mg when it is co-administered with the cardiac drug amiodarone and the drug labels for Zocor and generics as well as Vytorin have been updated to reflect this correction, according to a Drug Safety Communication issued by the agency on December 15, 2011. » More

FDA approves extended use of pneumococcal conjugate vaccine as a single dose to adults 50 years and older

FDA has approved Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] (Prevnar 13, Pfizer) as a single dose for use in adults aged 50 years and older.
» More

CONTINUING EDUCATION

MTM and collaborative practice

Successful collaborative relationships with physicians and other healthcare providers greatly enhance patient care. Knowing how to build those relationships is job 1. Earn up to 2 CPE credits. » Click here to login and take the exams.

CLINICAL NEWS

C. difficile recurrence less frequent with fidaxomicin than vancomycin, review shows

The recurrence of Clostridium difficile infection is less frequent with fidaxomicin than with vancomycin, according to a new review of the effectiveness of C. difficile treatments. » More

No observed clinical benefit for adding niacin to statins, halted study reports

Extended-release niacin demonstrated no clinical benefit as an add-on therapy to statins in patients with established coronary heart disease and low levels of baseline HDL cholesterol, according to the results of a study published December 15, 2011 in the New England Journal of Medicine. » More

Vitamin D, calcium supplementation show no affect on mortality, vascular disease in study

Daily vitamin D or calcium supplementation has no impact on mortality, vascular disease, cancer mortality, or cancer incidence, according to the results of a study published online November 23, 2011, in the Journal of Clinical Endocrinology & Metabolism. » More

Confirm your
e-newsletter subscription click here.

To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff

Voices

•	Anticoagulation update
•	JP at Large
•	View from the Zoo
•	Viewpoints
•	Regulatory & Legal

Meetings & Events

Digital Edition

•	View current edition

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.